## **SARS-COV-2 SEQUENCING**

**WEBINAR GIHSN** 

Antonin Bal, Gregory Destras, Hadrien Regue, Quentin Semanas, Gwendolyne Burfin, Bruno Simon, Bruno Lina, Laurence Josset


28/01/2021 NGS TEAM- CNR VIRUS RESPIRATOIRES FRANCE SUD

HOSPICES CIVILS DE LYON

www.chu-lyon.fr

## **SARS-COV-2 SEQUENCING**

**3 STEPS** 



## **METAGENOMICS-NGS**




#### **METAGENOMICS-NGS**

# Detection of known and unknown viruses

Universal method for viral detection and whole genome sequencing

February 2020



Influenza A &B, AdV, CMV, HHV-6, EBV, HBoV, HRV, RSV, PIV, MPV, CoV, Enterovirus, Measles, SARS-CoV-2

Bal et al., BMC Inf Dis, 2018

HCL



Molecular characterization of SARS-CoV-2 in the first COVID-19 cluster in France reveals an amino acid deletion in nsp2 (Asp268del)

A. Bal <sup>1, 2, 3, 4, \*</sup>, G. Destras <sup>1, 2, 3, \*</sup>, A. Gaymard <sup>1, 2, 3</sup>, M. Bouscambert-Duchamp <sup>1, 2</sup>, M. Valette <sup>1, 2</sup>, V. Escuret <sup>1, 2, 3</sup>, E. Frobert <sup>1, 2, 3</sup>, G. Billaud <sup>1, 2</sup>, S. Trouillet-Assant <sup>3, 4</sup>, V. Cheynet <sup>4</sup>, K. Brengel-Pesce <sup>4</sup>, F. Morfin <sup>1, 2, 3</sup>, B. Lina <sup>1, 2, 3</sup>, L. Josset <sup>1, 2, 3, \*</sup>

## PROS AND CONS FOR mNGS

#### **REFERENCE METHOD**

• Non-targeted method adapted for new emerging variant detection

- Low sensitivity: Ct<20
- Expensive
- Low throughput
- Time-consuming process

Charre, Virus Evol, 2020



## **AMPLICON-BASED APPROACHE**



## **AMPLICON-BASED APPROACHE**

#### ARTIC V3, 98 AMPLICONS ~400 BP

2) cDNA

synthesis and

amplification

1) RNA extraction 96-Well plate



5'		AAAA
→ →	← ← ← ← Hexamer	s and dT primer
	I	o ano or primer
	$\downarrow$	
5	3	
	5'	3'
	5' 3'	
5'	3'	
	*	
cDNA amplification		
5'	3	
Primer Pool 1	, <u>, , , , , , , , , , , , , , , , , , </u>	
	Ļ	
5'		
3'		
	+	
5' 📰 Primer Pool 2	3'	
Primer Pool 2		
	*	
5'	*	
5'	+	_
	*	
3		
	ls	_
3		
3'		
3' Combination of poo 5' 3'		
3' Combination of poo		

- 3) Lib preparation
- Illumina : DNA Prep/ Nextera XT , Tagmentation of reads
- ONT: sequencing of 400nt amplicons

#### 4) Illumina / ONT Sequencing



## **AMPLICON PROTOCOLS DERIVED FROM ARTIC**


#### COMMERCIAL OR IN-HOUSE PROTOCOLS

- COVID-Seq (Illumina)
- QIAseq SARS-CoV2 + FX DNA Lib Prep (Qiagen)
- NEBNext<sup>®</sup> ARTIC SARS-CoV-2 Companion Kit
- Wellcome Sanger Institute



#### **PROS AND CONS FOR AMPLICONS APPROACHES**

- Sensitivity
- Cost-effective
- High throughput
- Short-time process




 Impacted by little genome variations (SNPs or indels)

> HCL HOSPICES CIVILS DE LYON

Charre, Virus Evol, 2020


## **SARS-COV-2 SEQUENCING**

**3 STEPS** 



#### **BIOINFORMATICS**

#### FROM RAW DATA TO THE CONSENSUS SEQUENCE: ILLUMINA SEQUENCING





### **BIOINFORMATICS**

#### OPEN SOURCE AND COMMERCIAL SOLUTIONS

For Illumina users...



« SEQMET », our « in house » pipeline freely available here: <u>https://github.com/jossetlab/seqmet</u>





But see also the the Illumina's cloud solution « DRAGEN » Illumina can provide online data analysis without bioinformatic skills <u>https://basespace.illumina.com/</u>

... and ONT adepts

We haven't pipeline dedicated to ONT data analysis Several analysis workflows are proposed by ONT




https://labs.epi2me.io/ provide a large analysis panel (and tutorials) to process online your data



### **SARS-COV-2 SEQUENCING**

**3 STEPS** 





**NEGATIVE CONTROLS - CONTAMINATION** 

- 3 No-Template-Controls (NTC) per 96-well plate
- Nuclease free-water **processed through the whole** workflow (including extraction step)

### SARS-CoV-2 genome coverage for NTCs < 5%



#### POSITIVE CONTROL

- Viral isolate belonging to 20A clade
- Known mutations
- One positive control / 96-well plate

#### Viral genome coverage for positive control > 90%



#### COVERAGE

- Minimal depth of coverage / base for consensus sequence generation: 10X for Illumina sequencing
- Otherwise : N

# The sequence is validated if the genome coverage is > 90 % with a mean depth of coverage > 200X



#### NUMBER AND TYPE OF MUTATIONS

- Divergence (number of mutations): QC nextclade
- Frameshift mutation: CoV-GLUE / QC nextclade
- New mutations: CoV-GLUE
- Atypical set of mutation
- Molecular epidemiology (Clade not circulating in a given area)

Repeat extraction +/- mNGS




## **TOOLS FOR QUALITY CONTROL**



### NEXTCLADE

#### HTTPS://CLADES.NEXTSTRAIN.ORG/





Nextclade is currently under active development. Implementation details and data formats are subjects to change. The app may contain bugs. Please report any issues and leave feedback at github.com/nextstrain/nextclade HCL HOSPICES CIVILS DE LYON

#### NEXTCLADE

é	Nextclade			\$	Settings		i≡ Wr	nat's new		Engli	sh 🔻	<b>y</b> 1	1.1.11		¢	20A 21A (Do 21B) 98	eita) (fc/2002)		1288 - •
	Back   Don	e. Total se	quences: 384. Succeeded: 276. Failed: 108								G		T	<u>+</u>	1 ca	10	20 30	40 Infations	
ID ‡	Sequenc	e name	QC Clade	Mut.	non- ▲ ACGTN ↓ ?	Ns ?	Gaps	Ins.		N	ucleotide	e sequenc	e 🔻			*			
29	♥PI241-02111552140	)1_S84	NMPCFS 20I (Alpha, V1)	33	0	71	19	0								<b>A</b>			
32	PI241-02111552510	1_S67	verall QC score: 0	33	0	121	13	0				m			ТШ				
48	PI241-02111554830		verall QC status: good	32	0	121	13	0											
50	PI241-02111555260	01_S92 D	etailed QC assessment:	33	0	121	13	0											
51	PI241-02111555400	01_591	Missing Data: good	33	0	121	13	0											
53	PI241-02111555600		No issues Mixed Sites: good	32	0	121	13	0											
97	PI242-02111606330	2_S119	Mixed Sites: good No issues	29	0	124	18	0											
101	PI242-02111636610	1_S186	P Private Mutations: good	35	0	121	16	0							TIN				
102	PI242-02111636660	1_S187	No issues	34	0	126	13	0											
108	PI242-02111637150	1_S180	Mutation Clusters: good     No issues	37	0	121	13	0											
133	PI242-02111638870	1_598	Frame shifts: good	30	0	100	43	6		III -									
150	PI242-02111722390	)1_S132	No issues	29	0	177	47	0											
158	PI242-02111724630	1_S137	S Stop codons: good	32	0	289	47	0											
164	PI242-02111726300	1_S128	No issues	32	0	295	47	0											
170	PI242-02111728170	1_\$125	NMPCFS ZUH (Beta, VZ)	30	0	294	47	0											
193	PI243-02111719770	1_S198	NMPCFS 20H (Beta, V2)	33	0	237	47	0											
195	♥PI243-02111720170	1_S197	NMPCFS 20H (Beta, V2)	32	0	101	47	0											
198	PI243-02111720560	1_S196	NMPCFS 20H (Beta, V2)	32	0	291	47	0											
211	PI243-02111723960	1_S207	NMPCFS 20H (Beta, V2)	30	0	278	47	0											
214	♥PI243-02111724730	1_S206	NMPCFS 20H (Beta, V2)	32	0	281	47	0								-			
			Genome annotation ?												1.0	*			
									50	00 100	000 1	5000 2	0000	25000	0	-			

-L- 2008-728

0.0.0

60

HCL HOSPICES CIVILS DE LYON

#### **COV-GLUE**

#### HTTP://COV-GLUE.CVR.GLA.AC.UK/

#### • Listing of known substitutions, insertions and deletions

Summary	Genome visualis	visualisation Phylogenetic placen				Download sum	nmary 🗸	Download details <del>-</del>			
		Classification			Primer/p	robe analysis					
Sequence		hCoV- 19?	Lineage	Total LWR	Diagnost issues	ics Sequencing issues	Full repo	Differences from reference			
5C719_595		Yes	B.1.1	96.70%	4	1	View 🔗	SNPs: C913T, C3037T, C3267T, C5388A, C5986T, T6954C, C14408T, C14676T, C15279T, T16176C, A23063T, C23271A, A23403G, C23604A, C23709T, T24506G, G24914C, C27972T, G28048T, A28111G, G28280C, A28281T, T28282A, G28881A, G28882A, G28883C, C28977T Known amino acid replacement in nsp3: T1831 (Tree �) Known amino acid replacement in nsp3: A890D (Tree �) Known amino acid replacement in nsp3: I1412T (Tree �) Known amino acid replacement in nsp3: I1412T (Tree �) Known amino acid replacement in sp12: P323L (Tree �) Known amino acid replacement in S: N501Y (Tree �) Known amino acid replacement in S: N501Y (Tree �) Known amino acid replacement in S: P681H (Tree �) Known amino acid replacement in S: P681H (Tree �) Known amino acid replacement in S: S982A (Tree �) Known amino acid replacement in S: S982A (Tree �) Known amino acid replacement in ORF & 2027* (Tree �) Known amino acid replacement in ORF & S22A (Tree �) Known amino acid replacement in ORF & S22A (Tree �) Known amino acid replacement in ORF & S22A (Tree �) Known amino acid replacement in ORF & S73C (Tree �) Known amino acid replacement in ORF & S22A (Tree �) Known amino acid replacement in N: D3L (Tree �) Known amino acid replacement in N: S23SF (Tree �)			




#### **COV-GLUE**

#### HTTP://COV-GLUE.CVR.GLA.AC.UK/

• Genome visualisation tool


#### Analysis of sequence file 'tours.txt'





#### PANGOLIN

#### HTTPS://PANGOLIN.COG-UK.IO/



#### Pangolin COVID-19 Lineage Assigner

Phylogenetic Assignment of Named Global Outbreak LINeages



You can upload one or more sequences by dragging and dropping a (multi)fasta file or clicking "Select fasta file to upload" and selecting a (multi)fasta file.

This Web Application assigns lineages to COVID-19 sequenes based on the methodology described in this article


The software to assign lineages based on the algorithm that was developed by <u>Áine O'Toole, Verity Hill, JT</u> <u>McCrone, Emily Scher</u> and <u>Andrew Rambaut</u>. The source code can be found <u>here</u>


Recommended browsers 📀 🝅 or 🧭





#### **CREATING AN ACCOUNT**





HCL HOSPICES CIVILS

#### SUBMISSION OF SEQUENCES: BATCH OR PER SEQUENCE

	Flu™ EpiCoV™ My profile	1997) 1997) 1997)		
瞙 EpiCoV™ 🏼 🌏 Sear	ch 🥫 Downloads 🏼 🗐 Upload	🍯 My Unreleased		
A previously unknown hu City of Wuhan, who suffe	virus causing COVID-19 nan coronavirus (hCov-19) was first red from respiratory illnesses includ	ing atypical pneumonia, an	illness that	
host and is closely relat coronavirus (SARS). On 10. January 2020, the	ronavirus disease (COVID-19). The ed to the virus responsible for the e first virus genomes and associated	e Severe Acute Respiratory	/ Syndrome	
The World Health pandemic progr sequences to en identify potentia including sequer targets, phyloge				hal .
Analysis Updat	March     March 1000       March 1000     March 1000       March 1000			
- MAN ST	Single upload	_	Batch upload	ution in th year
Full genome derived from outbreak seque				

HCL HOSPICES CIVILS DE LYON

#### FASTA FILE (SEQ CONSENSUS) + EXCEL FILE (METADA)

EpiCoV™ 🜏 S	Search 🧃 Dowr	Iloads 🏾 🗐 Upload	じ My Unreleas	sed		
GISAID hCoV-19 Bat	ch Upload					
Upload genetic sequences of the sequence of th	uence as single F/ or CSV. Data wil	ASTA-File and meta be reviewed by a	data, available cli curator prior to re	nical and epidemi lease. An email co	ological data, geographi Infirmation will be issue	cal as well as species- 1 upon release.
Metadata as Excel or CSV*						
250						
	max size: 5M					
	max size. Jim	Choisir un fichier Auc	un tichier choisi			
Sequences as FASTA*						
	max size: 32M	Choisir un fichier Au	cun fichier choisi			
Report	Upload XLS/CSV	and EASTA	Aucun fic	hier choisi		
	001080 XE3/C3V	and TASIA.				

HCL HOSPICES CIVILS DE LYON

#### EXCEL FILE (METADA) = MANDATORY

Column information		
Submitter	mandatory	enter your GISAID-Username
FASTA filename	mandatory	the filename that contains the sequence without path (e.g. all_sequences.fasta not c:\users\meier\docs\all_sequences.fasta)
Virus name	mandatory	e.g. hCoV-19/Netherlands/Gelderland-01/2020 (Must be FASTA-Header from the FASTA file all_sequences.fasta)
Туре	mandatory	default must remain "betacoronavirus"
Passage details/history	mandatory	e.g. Original, Vero
Collection date	mandatory	Date in the format YYYY or YYYY-MM or YYYY-MM-DD
Location	mandatory	e.g. Europe / Germany / Bavaria / Munich
Additional location information		e.g. Cruise Ship, Convention, Live animal market
Host	mandatory	e.g. Human, Environment, Canine, Manis javanica, Rhinolophus affinis, etc
Additional host information		e.g. Patient infected while traveling in
Sampling Strategy		e.g. Sentinel surveillance (ILI), Sentinel surveillance (ARI), Sentinel surveillance (SARI), Non-sentinel-surveillance (hospital), Non-
		sentinel-surveillance (GP network), Longitudinal sampling on same patient(s), S gene dropout
Gender	mandatory	Male, Female, or unknown
Patient age	mandatory	e.g. 65 or 7 months, or unknown
Patient status	mandatory	e.g. Hospitalized, Released, Live, Deceased, or unknown
Specimen source		e.g. Sputum, Alveolar lavage fluid, Oro-pharyngeal swab, Blood, Tracheal swab, Urine, Stool, Cloakal swab, Organ, Feces, Other
Outbreak		Date, Location e.g. type of gathering, Family cluster, etc.
Last vaccinated		provide details if applicable
Treatment		Include drug name, dosage
Sequencing technology	mandatory	e.g. Illumina Miseq, Sanger, Nanopore MinION, Ion Torrent, etc.
Assembly method		e.g. CLC Genomics Workbench 12, Geneious 10.2.4, SPAdes/MEGAHIT v1.2.9, UGENE v. 33, etc.
Coverage		e.g. 70x, 1,000x, 10,000x (average)
Originating lab	mandatory	Where the clinical specimen or virus isolate was first obtained
Address	mandatory	
Sample ID given by the originating laborator		
Submitting lab	mandatory	Where sequence data have been generated and submitted to GISAID
Address	mandatory	5
Sample ID given by the submitting laboratory		
Authors	mandatory	a comma separated list of Authors with complete First followed by Last Name
Comment	leave empty	do not use this column
C	1	de at.:

### **GISAID: VIRUS NAME FOR GIHSN SEQUENCES**

Example

## hCoV-19/Ukraine/GIHSN-021073674801/2021

How can I find my sequence and the accession number?

GIS	AID					You are logg	ied in as <b>Antoni</b> i	n Bal - <u>logout</u>
Registered	Users EpiFlu™	<b>EpiCoV™</b> M	ly profile					
EpiCoV	M 🌏 Search 🧃	Downloads	🕘 Upload					
Search								
Accession ID		83	Virus name		~	🗌 complete 🕥	🗌 high covera	age 🕜
Location		~	Host		~	□ low coverage excl ⑦	w/Patient s	tatus 🔊 🔶
Collection	🥺 to	9	Submission	🎯 to	۲	collection date comp	0	
Clade	all 🗸 Lineage	~	Substitutions		✓ Varia	nts	✓ Reset	Fulltext

HCL HOSPICES CIVILS DE LYON

## **GISAID: VIRUS NAME FOR GIHSN SEQUENCES**

#### How can I find my sequence and the accession number?

earch	CNR Virus des Infections respiratoir	res								•
	Virus name	Passage de	Accession ID	Collection da	Submission E	i	Length	Host	Location	Originating
2	hCoV-19/France/ARA-HCL990000346767/2	Original	EPI_ISL_2676804	2021-06-17	2021-06-25		29 763	Human	Europe / France	CNR Vir
	hCoV-19/France/ARA-HCL990000346728/2	Original	EPI_ISL_2676803	2021-06-16	2021-06-25		29 763	Human	Europe / France	CNR Vir
	hCoV-19/France/ARA-HCL990000346540/2	Original	EPI_ISL_2676802	2021-06-17	2021-06-25	í	29 769	Human	Europe / France /	CNR Vir
	hCoV-19/France/ARA-HCL990000343952/2	Original	EPI_ISL_2676801	2021-06-12	2021-06-25	í	29 769	Human	Europe / France	CNR Vir
	hCoV-19/France/ARA-HCL990000341939/2	Original	EPI_ISL_2676800	2021-06-17	2021-06-25	٩	29 769	Human	Europe / France /	CNR Vir
	hCoV-19/France/ARA-HCL990000341874/2	Original	EPI_ISL_2676799	2021-06-17	2021-06-25	í	29 769	Human	Europe / France	CNR Vir
	hCoV-19/France/ARA-HCL990000340768/2	Original	EPI_ISL_2676798	2021-06-15	2021-06-25	٩	29 763	Human	Europe / France /	CNR Vir
	hCoV-19/France/ARA-HCL990000295086/2	Original	EPI_ISL_2676797	2021-06-14	2021-06-25	i	29 763	Human	Europe / France /	CNR Vir
	hCoV-19/France/ARA-HCL990000281949/2	Original	EPI_ISL_2676796	2021-06-05	2021-06-25	i	29 763	Human	Europe / France	CNR Vir
	hCoV-19/France/ARA-HCL121013879201/2	Original	EPI ISL 2676795	2021-06-16	2021-06-25	í	29 763	Human	Europe / France	CNR Vir

<< < 1 2 3 4 5 > >>



Analysis

Download

HCL

## **GISAID: VIRUS NAME FOR GIHSN SEQUENCES**

How can I find my sequence and the accession number?

E	piCoV™ 🌏 Search 🥛 Downloads	Upload	1			-	-			
earch	CNR Virus des Infections res Download	1	Sequences	s (FASTA)				-		
2	Virus name		○ Patient sta	. ,	metadata			ost	Location	Originating
	hCoV-19/France/ARA-HCL990000		<ul> <li>○ Dates and</li> <li>○ Input for the</li> </ul>	Location le Augur pipeli	ino			uman	Europe / France	CNR Vir
	hCoV-19/France/ARA-HCL990000			• • •	plemental table	e)		uman	Europe / France	CNR Vir
2	hCoV-19/France/ARA-HCL990000		🗹 Replace sp	paces with uno	derscores in FA	ASTA	header	uman	Europe / France	CNR Vir
	hCoV-19/France/ARA-HCL990000							uman	Europe / France	CNR Vir
1	hCoV-19/France/ARA-HCL990000							uman	Europe / France	CNR Vir
1	hCoV-19/France/ARA-HCL990000							uman	Europe / France	CNR Vir
1	hCoV-19/France/ARA-HCL990000	k					Downloa	uman	Europe / France	CNR Vir
1	hCoV-19/France/ARA-HCL990000					. 🛃	Download	uman	Europe / France	CNR Vir
1	hCoV-19/France/ARA-HCL990000281949/2	Driginal EP	PI_ISL_2676796	2021-06-05	2021-06-25	í	29 763	Human	Europe / France /	CNR Vir
	hCoV-19/France/ARA-HCL121013879201/2	Driginal EP	PI ISL 2676795	2021-06-16	2021-06-25	(j)	29 763	Human	Europe / France	CNR Vir

HCL HOSPICES CIVILS DE LYON

## **STORAGE / SHIPMENT**



## **STORAGE / SHIPMENT TO OUR LAB**

- RNA stored at -80°C until shipment
- Ct<28, 50 μl min
- Metadata excel file for GISAID Submission and recording : mandatory

Column information		
Submitter	mandatory	enter your GISAID-Username
FASTA filename		
		the filename that contains the sequence without path (e.g. all_sequences.fasta not c:\users\meier\docs\all_sequences.fasta)
Virus name		e.g. hCoV-19/Netherlands/Gelderland-01/2020 (Must be FASTA-Header from the FASTA file all_sequences.fasta)
Туре		default must remain "betacoronavirus"
Passage details/history	mandatory	e.g. Original, Vero
Collection date		Date in the format YYYY or YYYY-MM or YYYY-MM-DD
Location		e.g. Europe / Germany / Bavaria / Munich
Additional location information		e.g. Cruise Ship, Convention, Live animal market
Host	mandatory	e.g. Human, Environment, Canine, Manis javanica, Rhinolophus affinis, etc
Additional host information		e.g. Patient infected while traveling in
Sampling Strategy		e.g. Sentinel surveillance (ILI), Sentinel surveillance (ARI), Sentinel surveillance (SARI), Non-sentinel-surveillance (hospital), Non-
		sentinel-surveillance (GP network), Longitudinal sampling on same patient(s), S gene dropout
Gender	mandatory	Male, Female, or unknown
Patient age	mandatory	e.g. 65 or 7 months, or unknown
Patient status	mandatory	e.g. Hospitalized, Released, Live, Deceased, or unknown
Specimen source		e.g. Sputum, Alveolar lavage fluid, Oro-pharyngeal swab, Blood, Tracheal swab, Urine, Stool, Cloakal swab, Organ, Feces, Other
Outbreak		Date, Location e.g. type of gathering, Family cluster, etc.
Last vaccinated		provide details if applicable
Treatment		Include drug name, dosage
Sequencing technology	mandatory	e.g. Illumina Miseq, Sanger, Nanopore MinION, Ion Torrent, etc.
Assembly method		e.g. CLC Genomics Workbench 12, Geneious 10.2.4, SPAdes/MEGAHIT v1.2.9, UGENE v. 33, etc.
Coverage		e.g. 70x, 1,000x, 10,000x (average)
Originating lab	mandatory	Where the clinical specimen or virus isolate was first obtained
Address	mandatory	
Sample ID given by the originating laborator	y	
Submitting lab	mandatory	Where sequence data have been generated and submitted to GISAID
Address	mandatory	
Sample ID given by the submitting laboratory		
Authors	mandatory	a comma separated list of Authors with complete First followed by Last Name
Comment	leave empty	do not use this column
Commention	In all a second of	



## **STORAGE / SHIPMENT**

- Shipment organized by world courrier
  - File need to be completed and send to World courrier
  - They will take in charge the shipment :
    - Provide the boxes
    - Provide the dry ice

#### **HCL SAMPLES PROCESSED :**

- LEBANON: RNA 200 SAMPLES SENT SEQUENCING OK
- UKRAINE : RNA 43 SAMPLES SENT SEQUENCING IN PROGRESS



Customer	Order	Form
----------	-------	------

Account#: Billing Reference	Account Name:		
Your Name: Your E-mail:		Your Phone	#:
Would you like to	o receive automatic email alerts?	Order Entry:	Pick-up: Delivery:
Pick-up From:	Company Name	Deliver To:	Company Name
	Contact Name		Contact Name
	Street Address		Street Address
	Street Address		Street Address
	City, State/Province, Zip Country		City, State/Province, Zip Country
	Contact Phone Number		Contact Phone Number
Auto Alerts?	Contact E-mail	Auto Alerts?	Contact Email
Order Entry:	Pick-up: Delivery:	Order Entry:	Pick-up: Delivery:
Pick-up Date:	Time:	(leave blan	k to just pre-advise paperwork)
Product Descrip	tion:		
Hazardous? (	YES NO If Yes: UN#	Class:	
Number of Piece	es:* Total Weight:	Dimensions:	
Value for Custor	ns: Incoterms:		0 0
Shipments over	\$2500 or shipments subject to export license	e require EEI/SED.	
If you would like	WC to file the SED for you, please fill out th	e Shipper's Letter of I	nstructions section below.
If you will file yo	ur own SED, please advise the ITN#:		
SHIPPER'S LETTE	R OF INSTRUCTIONS:		
This section shou	Ild only be completed if you would like WC to	o file the SED on your l	behalf.
Type of transact	ion: O Routed O Non-routed		
Parties to transa	action: 🔘 Related 🔘 Non-related		
Ultimate Consig	nee Type: O Direct Consumer	Government entity	Reseller O Other/Unknown
License Value:			
	U.S. Principal Party of Interest (USPPI):		Foreign Principal Party of Interest:



#### **SARS-COV-2 SEQUENCING INDICATIONS**



## **SARS-COV-2 SEQUENCING INDICATIONS**

- Genomic surveillance: detect and monitor new variant of concern
- Cluster investigation
- Targeted sequencing of SARS-CoV-2 cases from special settings or populations
  - Vaccine breakthrough infections (COVID-IVAC Study) and reinfections
  - Immunocompromised patients : detecting new variant and treatment monitoring

HCL

## **CONCLUSION :**

- Long +/- manual process = potential errors at all steps
- Validation criteria must be respected
- Need to be critical: re-sequence + possible control by mNGS
- Sharing of sequences on GISAID (date + location)
- Random genomic surveillance / targeted sequencing
- Quality of sequencing (wet, dry, validation) = crucial for analysis and interpretation



#### **EPI**démiologique des maladies Infectieuses **MERCI** Public resources for SARS-CoV-2 **Respiratory virus National Reference Center (NRC) :** genome analysis : NGS team Pr Florence Morfin GISAID • Dr Laurence Josset Dr Alexandre Gaymard **NextStrain** Dr Antonin Bal Dr Emilie Frobert **COV-GLUE** Dr Grégory Destras Dr Martine Valette Dr Bruno Simon Pr Bruno Lina Grégory Quéromès (PhD Student) Hadrien Regue (Bioinformatician) Gwendolyne Burfin (technician) HCL Quentin Semanas (technician) **HOSPICES CIVILS** www.chu-lyon.fr **DE LYON** 0000

**GEN**omique